{"entity":{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","aka":[],"tldr":"A phase 3 trial of Cabozantinib in thyroid cancer, run by Exelixis, active and no longer recruiting.","summary":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy is a phase 3 interventional study registered as NCT03690388 by Exelixis, with 187 participants enrolled, started 2018-10-05 and due to reach its primary completion in 2020-08-19. Interventions recorded: Cabozantinib, Placebo. Conditions listed: Differentiated Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2023; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03690388","url":"https://clinicaltrials.gov/study/NCT03690388"}],"tags":["ctgov-ingest"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["cabozantinib"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03690388","phase":"3","setting":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy","sponsor":"Exelixis","started":"2018-10-05","startedType":"actual","yearReported":2023,"enrolled":187,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Cabozantinib","n":125,"note":"The CI 5.7 to 0.0 is not 0.0 but NA. The median PFS and upper bound of the CI could not be determined because not enough subjects on the cabozantinib arm had e…; Figures from the ClinicalTrials.gov results section (first posted 2023-05-18), not from a publication"},{"name":"Placebo","n":62,"value":1.9,"note":"96% CI 1.8 to 3.6"}],"hr":0.22,"p":"<0.0001","source":"https://clinicaltrials.gov/study/NCT03690388?tab=results"},{"endpoint":"Objective Response Rate (ORR)","primary":true,"unit":"%","arms":[{"name":"Cabozantinib","n":67,"value":15,"note":"99% CI 5.8 to 29.3; Figures from the ClinicalTrials.gov results section (first posted 2023-05-18), not from a publication"},{"name":"Placebo","n":33,"value":0,"note":"99% CI 0.0 to 14.8"}],"source":"https://clinicaltrials.gov/study/NCT03690388?tab=results"}]},"route":"/trials/nct03690388/","neighbours":{"cancer":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}]}}